The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

DH Mathalon; S Nicholas; BJ Roach; T Billah; S Lavoie; T Whitford; HK Hamilton; L Addamo; A Anohkin; T Bekinschtein; A Belger; K Buccilli; J Cahill; RE Carrión; S Damiani; I Dzafic; BH Ebdrup; I Izyurov; J Jarcho; R Jenni; A Jo; S Kerins; C Lee; EA Martin; R Mayol-Troncoso; MA Niznikiewicz; M Parvaz; O Pogarell; J Prieto-Montalvo; R Rabin; DR Roalf; J Rogers; DF Salisbury; R Shaik; S Shankman; MC Stevens; YN Suen; NC Swann; X Tang; JL Thompson; I Tso; J Wenzel; JH Zhou; J Addington; L Alameda; C Arango; NJK Breitborde; MR Broome; KS Cadenhead; ME Calkins; RI Castillo-Passi; EYH Chen; J Choi; P Conus; CM Corcoran; BA Cornblatt; CM Diaz-Caneja; LM Ellman; P Fusar-Poli; PA Gaspar; C Gerber; LB Glenthøj; LE Horton; CLM Hui; J Kambeitz; L Kambeitz-Ilankovic; MS Keshavan; M Kim; SW Kim; N Koutsouleris; JS Kwon; K Langbein; D Mamah; VA Mittal; M Nordentoft; GD Pearlson; J Perez; DO Perkins; AR Powers; FW Sabb; J Schiffman; JL Shah; SM Silverstein; S Smesny; WS Stone; GP Strauss; R Upthegrove; SK Verma; J Wang; DH Wolf; T Zhang; S Bouix; O Pasternak; KIK Cho; MJ Coleman; D Dwyer; A Nunez; Z Tamayo; SJ Wood; RS Kahn

Journal article

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

DH Mathalon, S Nicholas, BJ Roach, T Billah, S Lavoie, T Whitford, HK Hamilton, L Addamo, A Anohkin, T Bekinschtein, A Belger, K Buccilli, J Cahill, RE Carrión, S Damiani, I Dzafic, BH Ebdrup, I Izyurov, J Jarcho, R Jenni Show all

Schizophrenia | Published : 2025

DOI: 10.1038/s41537-025-00622-0

Open access

Abstract

Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimu..

View full abstract